| $350M | ||
| $172M | ||
| $127M | ||
| $109M | ||
| $107M | ||
| $100M |
Buys | $136,006 | 7 | 100 |
Sells | $0 | 0 | 0 |
| CERRONE GABRIELE M | 2 | $67,625 | 0 | $0 | $67,625 | |
| Mantelli Flavio | CHIEF MEDICAL OFFICER | 1 | $28,000 | 0 | $0 | $28,000 |
| Dempsey Robert John | CHIEF EXECUTIVE OFFICER | 1 | $23,085 | 0 | $0 | $23,085 |
| BRANCACCIO JOHN P | director | 1 | $7,385 | 0 | $0 | $7,385 |
| Patil Rajkumar V. | Chief Scientific Officer | 1 | $5,011 | 0 | $0 | $5,011 |
| JACOB GARY S | CHIEF DEVELOPMENT OFFICER | 1 | $4,900 | 0 | $0 | $4,900 |
OKYO Pharma Limited is a biopharmaceutical firm operating at the preclinical stage, dedicated to developing innovative treatments for individuals in the United Kingdom experiencing inflammatory eye conditions and ocular discomfort. Its primary therapeutic candidate is OK-101, specifically designed to address dry eye disease. Additionally, the company is advancing OK-201, an experimental bovine adrenal medulla lipidated-peptide analogue, intended to treat neuropathic ocular pain. Established in 2007, OKYO Pharma Limited maintains its headquarters in London, UK.
Over the last 12 months, insiders at OKYO Pharma Limited have bought $136,006 and sold $0 worth of OKYO Pharma Limited stock.
On average, over the past 5 years, insiders at OKYO Pharma Limited have bought $299,520 and sold $0 worth of stock each year.
Highest buying activity among insiders over the last 12 months: CERRONE GABRIELE M () — $67,625. Mantelli Flavio (CHIEF MEDICAL OFFICER) — $28,000. Dempsey Robert John (CHIEF EXECUTIVE OFFICER) — $23,085.
The last purchase of 3,363 shares for transaction amount of $5,011 was made by Patil Rajkumar V. (Chief Scientific Officer) on 2026‑07‑27.
| 2026-07-27 | Patil Rajkumar V. | Chief Scientific Officer | 3,363 0.008% | $1.49 | $5,011 | -5.49% | ||
| 2026-07-22 | Dempsey Robert John | CHIEF EXECUTIVE OFFICER | 15,000 0.0396% | $1.54 | $23,085 | +1.97% | ||
| 2026-07-21 | CERRONE GABRIELE M | 22,500 0.0591% | $1.45 | $32,625 | +7.64% | |||
| 2026-07-21 | JACOB GARY S | CHIEF DEVELOPMENT OFFICER | 3,500 0.0089% | $1.40 | $4,900 | +7.64% | ||
| 2026-07-21 | BRANCACCIO JOHN P | director | 5,000 0.0134% | $1.48 | $7,385 | +7.64% | ||
| 2026-07-21 | Mantelli Flavio | CHIEF MEDICAL OFFICER | 20,000 0.0507% | $1.40 | $28,000 | +7.64% | ||
| 2026-07-20 | CERRONE GABRIELE M | 25,000 0.0666% | $1.40 | $35,000 | +12.77% | |||
| 2023-09-15 | BRANCACCIO JOHN P | director | 16,670 0.0722% | $1.50 | $25,005 | -25.13% | ||
| 2022-05-19 | CERRONE GABRIELE M | Non-Executive Chairman | 5.84M 1.7068% | $0.10 | $590,800 | -36.04% | ||
| 2022-05-19 | JACOB GARY S | Chief Executive Officer | 12,500 0.1445% | $4.00 | $50,000 | -36.04% | ||
| 2022-05-17 | CERRONE GABRIELE M | Non-Executive Chairman | 25,000 0.2795% | $3.87 | $96,750 | -40.88% |
| CERRONE GABRIELE M | 10873916 28.3418% | $17.07M | 4 | 0 | <0.0001% | |
| JACOB GARY S | CHIEF DEVELOPMENT OFFICER | 112420 0.293% | $176,499.40 | 2 | 0 | <0.0001% |
| BRANCACCIO JOHN P | director | 35201 0.0917% | $55,265.57 | 2 | 0 | <0.0001% |
| Patil Rajkumar V. | Chief Scientific Officer | 20030 0.0522% | $31,447.10 | 1 | 0 | |
| Mantelli Flavio | CHIEF MEDICAL OFFICER | 20000 0.0521% | $31,400.00 | 1 | 0 | |
| Dempsey Robert John | CHIEF EXECUTIVE OFFICER | 15000 0.0391% | $23,550.00 | 1 | 0 |
$155,630,608 | 79 | -24.53% | $56.52M | |
$24,478,755 | 37 | -34.59% | $49.2M | |
$909,129 | 37 | 42.19% | $72.52M | |
$6,818,859 | 36 | 47.81% | $72.11M | |
$115,646,156 | 35 | 16.45% | $65.09M | |
$2,783,837 | 22 | -18.19% | $64.87M | |
$17,594,514 | 16 | -20.37% | $57.99M | |
$1,091,554 | 14 | -16.96% | $60.33M | |
$31,682,927 | 12 | -55.94% | $59.18M | |
$20,042,003 | 10 | -19.50% | $54.7M | |
$22,090,972 | 7 | -3.49% | $70.06M | |
$106,599,960 | 6 | -7.63% | $68.8M | |
$45,000,000 | 6 | -31.22% | $51.41M | |
$401,951 | 4 | 57.41% | $67.07M | |
$657,791 | 4 | -52.05% | $59.13M | |
OKYO Pharma Limited (OKYO) | $762,555 | 4 | -34.52% | $60.24M |
$12,498 | 2 | 39.61% | $51.46M | |
$19,175,155 | 2 | 40.00% | $55.39M | |
$10,629 | 1 | -0.59% | $63.58M |
| Increased Positions | 5 | +50% | 117,517 | +4.57% |
| Decreased Positions | 3 | -30% | 2M | -78.69% |
| New Positions | 4 | New | 20,717 | New |
| Sold Out Positions | 2 | Sold Out | 72,513 | Sold Out |
| Total Postitions | 12 | +20% | 665,294 | -74.12% |
| Dauntless Investment Group, Llc | $5,401.00 | 6.37% | 2.42M | -313,732 | -11.47% | 2025-09-30 |
| Northern Trust Corp | $127.00 | 0.15% | 57,158 | +57,158 | New | 2025-09-30 |
| Renaissance Technologies Llc | $92.00 | 0.11% | 41,200 | +41,200 | New | 2025-09-30 |
| Citadel Advisors Llc | $34.00 | 0.04% | 15,355 | +15,355 | New | 2025-09-30 |
| Cerity Partners Llc | $29.00 | 0.03% | 12,812 | 0 | 0% | 2025-09-30 |
| Geode Capital Management, Llc | $27.00 | 0.03% | 12,090 | 0 | 0% | 2025-09-30 |
| Wealth Enhancement Advisory Services, Llc | $22.00 | 0.03% | 10,000 | 0 | 0% | 2025-09-30 |
| Osaic Holdings, Inc. | $0 | 0% | 152 | +152 | New | 2025-09-30 |
| Ubs Group Ag | $0 | 0% | 0 | -115 | Sold Out | 2025-09-30 |